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Abstract
Background: Recent evidence suggests that human breast cancer is sustained by a minor subpopulation of breast tumor-
initiating cells (BTIC), which confer resistance to anticancer therapies and consequently must be eradicated to achieve
durable breast cancer cure.
Methods/Findings: To identify signaling pathways that might be targeted to eliminate BTIC, while sparing their normal
stem and progenitor cell counterparts, we performed global gene expression profiling of BTIC- and mammary epithelial
stem/progenitor cell- enriched cultures derived from mouse mammary tumors and mammary glands, respectively. Such
analyses suggested a role for the Wnt/Beta-catenin signaling pathway in maintaining the viability and or sustaining the self-
renewal of BTICs in vitro. To determine whether the Wnt/Beta-catenin pathway played a role in BTIC processes we employed
a chemical genomics approach. We found that pharmacological inhibitors of Wnt/b-catenin signaling inhibited sphere- and
colony-formation by primary breast tumor cells and primary mammary epithelial cells, as well as by tumorsphere- and
mammosphere-derived cells. Serial assays of self-renewal in vitro revealed that the Wnt/Beta-catenin signaling inhibitor
PKF118–310 irreversibly affected BTIC, whereas it functioned reversibly to suspend the self-renewal of mammary epithelial
stem/progenitor cells. Incubation of primary tumor cells in vitro with PKF118–310 eliminated their capacity to subsequently
seed tumor growth after transplant into syngeneic mice. Administration of PKF118–310 to tumor-bearing mice halted
tumor growth in vivo. Moreover, viable tumor cells harvested from PKF118–310 treated mice were unable to seed the
growth of secondary tumors after transplant.
Conclusions: These studies demonstrate that inhibitors of Wnt/b-catenin signaling eradicated BTIC in vitro and in vivo and
provide a compelling rationale for developing such antagonists for breast cancer therapy.
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Introduction
Recent findings suggest that human tumors exist as cellular
hierarchies composed of tumorigenic and non-tumorigenic cells
[1]. The occurrence of functionally-distinct tumorigenic cell
compartments was demonstrated by separating tumor cells into
different fractions based on their expression of cell surface
markers, and transplanting the various fractions into immune-
deficient mice [2]. Only some tumor cell fractions were capable of
engrafting and eliciting tumor growth in mice, whereas others
could not, even when large numbers of cells were transplanted
suggesting that only a subset of tumor cells is capable of initiating
tumor growth. Tumor-initiating cells (TICs), also commonly
termed cancer stem cells, are thought to drive tumor growth,
seed metastases and account for tumor relapse after remission [1].
In this model of tumor cell biology, TICs self-renew and
differentiate giving rise to both tumorigenic and non-tumorigenic
cells that make up the bulk neoplastic cell population. For
example, human breast tumors can be fractionated into tumor-
igenic and non-tumorigenic cell populations based on their
expression of the cell surface markers CD44 and CD24 [3].
Whereas only 0.01% of the bulk tumor cells were capable of
seeding tumor growth in NOD/SCID mice, 0.5% of the
CD44
+CD24
2/low: Lineage
2 fraction was able to engraft and
give rise to tumors. Furthermore, the tumor xenografts seeded by
cells from the CD44
+CD24
2/low: Lineage
2 fraction comprised the
same cellular heterogeneity observed in the original tumor. TICs
were originally identified in leukemia [2], and more recently in
epithelial tumors of the breast [3], brain [4], prostate [5], gastro-
intestinal tract [6,7], skin [8], ovaries [9], and head and neck [10].
Hence TICs underlie a significant proportion of all malignancies.
The discovery of TICs has important implications for cancer
therapy, namely that cancer treatments need to eliminate these
cells to provide durable cure. Most current anticancer therapies
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tumor cell lines and to shrink xenografts in mice that were seeded
by these same cell lines [11,12]. However, tumor cell lines and
their xenografts generally comprise relatively few TICs and as a
result most current chemotherapies target the non-tumorigenic
cells, which make up the bulk tumor mass. TICs possess increased
chemotherapeutic resistance [13,14,15,16,17,18], and decreased
sensitivity to radiation therapy [19,20,21], properties that allow
them to circumvent the killing effects of these commonly used
anticancer agents. Hence TICs likely survive frontline cancer
therapeutics and may account for cancer recurrence. The key to
providing long-term cancer cure is to find a means to destroy TIC
or abrogate their tumorigenicity thus eliminating tumor recur-
rence.
Identifying signaling pathways required for the survival and self-
renewal of BTICs but not for their mammary epithelial stem cell
counterparts may provide new molecular targets for anticancer
drug discovery. However, studies of human BTICs have been
confounded by their scarcity in tumors, the inability to isolate
them as pure populations and means to readily culture them
in vitro under conditions that maintain their tumorigenicity
[2,3,4,5,6,7,10]. Additionally, most studies of human BTICs have
not compared these cells to their normal stem cell counterparts.
Such comparative analyses are likely necessary if we are to find
therapies that selectively eradicate BTICs while sparing normal
stem cells.
To overcome these limitations of human BTIC, we’ve
investigated these cells in breast cancer-prone transgenic mice
such as those that model ERBB2-positive breast cancer [22]. We
found that mammary tumors of transgenic mice comprise ,30%
BTICs and that cells from these tumors can be propagated in vitro
as non-adherent tumorspheres, which also comprise a similarly
high fraction of BTICs [23]. We have also used these same culture
conditions to propagate mouse mammary epithelial stem and
progenitor cell cultures as non-adherent mammospheres, which
serve as a normal stem/progenitor cell controls to compliment our
studies of BTICs [23]. Here, we exploit the mouse breast cancer
model to demonstrate that agents, which inhibit Wnt/Beta-catenin
signaling, selectively target BTIC.
Results
Expression of Wnt/b-catenin signaling pathway
components and target genes
Numerous previous studies have linked activation of Wnt/b-
catenin signaling with breast cancer [21,24,25,26,27,28,29,30,
31,32,33,34]. We sought to extend these findings by first
investigating the expression of Wnt/b-catenin signaling pathway
components in mouse tumorspheres, mammospheres, and mam-
mospheres induced to differentiate in vitro, which we used as
approximate in vitro models of BTICs, mammary epithelial stem
and progenitor cells, and differentiated mammary epithelial cells,
respectively. A microarray analysis of 3 independent tumorsphere
cultures established from independent mouse mammary tumors
and 3 separate preparations of mammospheres and mammo-
spheres induced to differentiate in vitro, revealed that the
transcripts of many Wnt/b-catenin signaling pathway genes were
most highly expressed in tumorspheres relative to either mammo-
spheres or mammospheres induced to differentiate (Fig. 1A). The
latter included upstream pathway components such as Wnt
ligands, receptors, as well as the transcriptional co-activator
TCF4 (Fig. 1A). Several Wnt/b-catenin target genes were also
most highly expressed in tumorspheres, including Axin2, cyclinD1
and CD44. Interestingly, the expression of transcripts encoding
inhibitory Wnt/b-catenin signaling pathway elements, such as
Sfrp1, Srfp2 and Dkk2, were highest in mammospheres induced to
differentiate, compared to both mammospheres and tumorspheres
(Fig. 1A).
To verify the global gene expression profiling data we
performed quantitative RT-PCR with primers that identified
transcripts encoding components and downstream targets of the
Wnt/b-catenin signaling pathway using additional independent
preparations of RNA isolated from tumorspheres (n=3), mammo-
spheres (n=3), and mammospheres induced to differentiate
(n=3), respectively. These analysis confirmed our original
findings, namely that transcripts of components and target genes
of the Wnt/b–catenin signaling pathway were generally more
highly expressed in tumorspheres compared to either mammop-
sheres or mammopsheres induced to differentiate in vitro (Fig. 1B–
E, *p,0.05 for all genes shown, t-test). For example, Wnt7A and
7B, as well as the Fzd4 and 6 receptors were most highly expressed
in tumorspheres compared to either mammospheres or mammo-
spheres induced to differentiate in vitro (Fig. 1 B&D). By contrast,
mammospheres and mammospheres induced to differentiate
expressed higher levels of transcripts that encode negative
regulators of the Wnt pathway, such as Frzb, Sfrp2 and Sfrp4
(Fig. 1 C & E).
We also investigated whether the finding of differential
expression of Wnt/b-catenin signaling pathway components and
target genes using the in vitro models were relevant to human breast
cancer patients. To this end we used whole tumor gene expression
profiles derived from human breast tumor RNA samples with
accompanying overall- and metastasis free survival data [35]. We
identified a Wnt-based BTIC gene signature that comprised
differentially expressed genes between tumorspheres and mammo-
spheres that were induced to differentiate in vitro. We mapped
these genes onto their human orthologs present in the previously
published NKI whole tumor gene expression data set (Table 1).
We then used the gene signature to learn whether we could
separate patient tumor specimens from the NKI data set into
tumorsphere-related and mammospheres induced to differentiate-
related groups (tumorsphere-unrelated) [36]. Notably, the expres-
sion of tumorsphere-related Wnt/b-catenin signaling pathway
genes was linked to poor overall survival (Fig. 1F, *p=0.0005, log-
rank test) and decreased metastasis-free survival (Fig. 1G,
*p=0.0068, log-rank test) when compared with the expression
of mammospheres induced to differentiate-related Wnt/b-catenin
signaling pathway genes. These data suggests that activated Wnt/
b-catenin signaling may be a unique feature of BTICs derived
from mouse mammary tumors relative to mammary epithelial
stem and progenitor cells, and that Wnt/b-catenin pathway
activation in BTICs may be linked to human breast cancer patient
outcome and metastasis.
Wnt/b-catenin pathway agonists and antagonists
regulate self-renewal and proliferation of BTIC and
mammary epithelial stem/progenitor cells
To determine whether Wnt/b-catenin signaling was required
for BTIC and mammary epithelial stem and progenitor cell
function in vitro, we examined the effect of agonists and antagonists
of Wnt/b-catenin signaling on sphere formation, which when
performed under appropriate conditions [37] is thought to be an
attribute of stem/progenitor cells and TICs [37,38,39,40]. We
seeded dispersed cells dissociated from mammospheres and
tumorspheres into media containing either Dkk1 or Wnt3a at
concentrations previously shown to be sufficient to inhibit or
activate the Wnt/b-catenin signaling pathway, respectively
[41,42]. Dkk1 is a secreted protein inhibitor [43], and Wnt3A is
Wnt Inhibitors Target Breast Cancer Stem Cells
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reduced sphere formation, whereas addition of Wnt3A stimulated
sphere formation of both mammosphere- and tumorsphere-
derived cells (Fig. 2A). We used the small molecule BIO to inhibit
GSKb, a negative regulator of Wnt/b-catenin signaling [44].
Addition of BIO at various concentrations stimulated sphere
formation by both mammospheres- and tumorsphere-derived cells
in a dose-dependent manner (Fig. 2B).
We similarly tested pharmacological agents, which target Wnt/
b-catenin signaling (PKF118–310, PKF115–584, CGP049090),
for their affect on sphere formation. These inhibitors are specific
antagonists of Wnt/b-catenin signaling that interrupt the penul-
timate step in pathway activation, namely the interaction between
b-catenin and Tcf/Lef transcription factors [45]. We seeded
freshly isolated primary tumor cells and primary mammary
epithelial cells, as well as mammosphere- and tumorsphere-
derived cells into medium containing various concentrations of the
inhibitors. Each inhibitor reduced sphere formation by primary
tumor cells and primary mammary epithelial cells (Fig. 2C), as well
as by mammosphere- and tumorsphere-derived cells (Fig. 2D), in a
dose dependent fashion. Notably, the inhibitory concentration of
the compounds required to reduce sphere formation by 50%
(IC50) (Table 2) did not significantly differ from those IC50 values
reported previously to affect reduce Tcf-dependent reporter gene
expression in cell lines (Table 2) [45].
We also assessed the effects of the compounds on colony
formation, an assay commonly used to enumerate stem and
progenitor cells [46]. We seeded freshly isolated primary tumor
cells and primary mammary epithelial cells, as well as mammo-
sphere- and tumorsphere-derived cells at clonal cell density into
collagen-coated plates in serum-containing medium. When
colonies appeared, generally a week later, they were stained and
counted. The inhibitors reduced colony formation by primary
tumor cells and mammary epithelial cells (Fig. 2E), as well as that
of mammosphere- and tumorsphere derived cells in a concentra-
tion dependent fashion (Fig. 2F). Inhibition of both colony and
sphere formation occurred at similar inhibitor concentrations,
suggesting that the inhibitors targeted both progenitor cells and
stem cells as well as their tumor equivalent counterparts.
To learn whether the inhibitory compounds affected the self-
renewal of sphere-forming cells, we investigated the capacity of
cells exposed to the compounds to serially form spheres. In short,
dispersed primary mammary epithelial cells and primary tumor
cells were exposed to PKF118–310 during a 4-day primary sphere-
forming assay. The spheres that formed were counted, the cells
dissociated from the spheres and the dispersed cells plated to form
secondary spheres in fresh medium lacking the inhibitors. As we
previously demonstrated, PKF118–310 reduced primary sphere-
formation by both primary tumor cells and primary mammary
epithelial cells dependent on its concentration (Fig. 3A&B).
However, whereas the primary mammary epithelial cells treated
with 1 mM PKF118–310 formed new mammospheres in second-
ary sphere-forming assays at the same frequency as the vehicle-
treated mammary epithelial cells (Fig. 3C), the primary tumor cells
exposed to 1 mM PKF118–310 exhibited a ,10 fold reduced
capacity to form spheres relative to the vehicle-treated primary
tumor cells (Fig. 3D, *p,0.05). These observations demonstrate
that a single exposure of tumor cells to PKF118–310 was sufficient
Figure 1. Expression of Wnt pathway genes in tumorspheres (TMS), mammospheres (MMS) and mammospheres induced to
differentiate (diffMMS). A) Heat maps of 3 independent TMS (A, n=3), MMS (B, n=3) and diffMMS (C, n=3) RNA preparations profiled on
MOE430A Gene Chips. B–E) qRT-PCR of transcripts encoding components and target genes of the Wnt signaling pathway (* p,0.05, t-test) for all
genes shown. F and G) Survival, (*p=0.005, Log-rank test) and metastasis (*p=0.0068, Log-rank test), curves for human breast cancer patients
classified based on their expression of TMS-related and TMS-unrelated (diffMMS-related) specific Wnt pathway components.
doi:10.1371/journal.pone.0033976.g001
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PKF118–310 was no longer present in the medium. Conversely,
mammary epithelial cells similarly exposed to PKF118–310 were
not impaired in their sphere forming capacity, suggesting that the
irreversible effect of PKF118–310 was limited to the primary
tumor cells. These findings suggest that PKF118–310 reversibly
affected the self-renewal of mammary epithelial cells in vitro but
irreversibly affected the self-renewal of the primary breast tumor
cells.
Our data suggesting that knock down of Wnt/b-catenin
signaling by PKF118–310 irreversibly blocked the self-renewal of
tumorsphere-initiating cells in vitro, prompted us to test whether
this inhibitor specifically affected the capacity of BTICs to elicit
tumor growth in syngeneic mice after tumor cell transplant. We
incubated freshly isolated primary tumor cells under sphere
forming conditions in presence of vehicle (DMSO) or PKF118–
310 (1 mM or 2.5 mM concentrations). After 4 days the spheres
were collected, dissociated and equal numbers (5,000) of viable
PKF118–310- and vehicle-treated cells were injected sub-cutane-
ously into the syngeneic mice. Upon endpoint, when the tumor in
any individual mouse reached 10% of its weight (,6 weeks) all the
animals were sacrificed and the tumors harvested. Tumors that
arose from tumor cells incubated with PKF118–310 (1 mM)
appeared with longer latency and were approximately 50%
smaller at endpoint than those that arose from vehicle-treated
tumor cells (control [m=0.49 g], treatment [m=0.26 g],
*p,0.05) (Fig. 3E). Furthermore, when higher doses of
PKF118–310 (2.5 mM) were used in these experiments, the tumor
cells exposed to this concentration of the compound failed to
initiate tumor growth in any of the host mice (Fig. 3F, *p,0.05,
,6 weeks). Collectively, these data demonstrate that incubation of
primary tumor cells with PKF118–310 for 4 days in vitro
substantially reduced BTIC frequency.
PKF118–310 halts tumor growth in vivo
Our data suggested that incubation of primary breast tumor
cells in vitro with PKF118–310 substantially reduced BTIC
frequency as assessed by cell transplant into syngeneic mice. To
determine whether PKF118–310 affected the growth of pre-
established breast tumors and reduced BTIC frequency in vivo,w e
transplanted primary breast tumor cells into syngeneic mice and
treated these hosts with PKF118–310 after the tumors had
reached a volume of ,1c m
3. We found that treating tumor-
bearing mice with 0.85 mg/kg of PKF118–310 for 12 days (5 days
on, 2 days off and 5 days on) inhibited tumor growth compared to
their vehicle-treated counterparts, but did not induce significant
tumor regression during the treatment period (Fig. 4A). After
treatment ceased the tumors in mice administered the vehicle were
,3 fold larger than those in PKF118–310-treated mice (Fig. 4B,
*p,0.05).
To uncover potential mechanisms whereby the compound
halted tumor growth, we prepared sections from the tumors of
both cohorts and stained them with Hematoxylin and Eosin
(H&E). Interestingly the tumors of the mice treated with PKF118–
310 contained many cell-free areas that were often circumscribed
by a ring of cells resembling a duct (Fig. 4C). In some cases the
cell-free areas contained material, characteristic of milk protein
secretions. Interestingly, the changes in histology induced by
treatment with PKF118–310 are consistent with reduced tumor
grade, a histological parameter associated with better survival
outcomes in human breast cancer patients [47]. We also examined
whether inhibition of tumor growth was accomplished by a
reduction in cell proliferation and/or induction of apoptosis. We
stained tumor sections for markers of proliferation (Ki67) and
apoptosis (cleaved caspase-3 and TUNEL). We observed a
significant decrease in the frequency of Ki67 positive tumor cell
nuclei in the PKF118–310 treated tumor-bearing mice compared
to their vehicle-treated counterparts (Fig. 4D&E). We did not
observe any positive staining for cleaved caspase-3 or TUNEL in
tumors from either vehicle- or PKF118–310-treated mice (data not
shown). Tumors from PKF118–310 treated mice comprised
approximately 3–4-fold fewer Ki67-positive cells than tumors
from vehicle-treated mice. We similarly simultaneously stained the
tumor sections with antibodies to a luminal lineage marker (CK8)
and with those to each of two myoepithelial lineage markers
(CK14 and alpha-smooth muscle actin [alpha-SMA). The vast
majority of the cells in sections prepared from tumors of the
vehicle-treated mice expressed only the luminal lineage marker in
keeping with previous findings (data not shown). Tumor sections
prepared from tumors of the mice administered PKF118–310 also
only expressed the luminal lineage marker. Surprisingly the cells
comprising the duct-like structures found in tumor sections of mice
administered PKF118–310 expressed the luminal lineage marker
but not either of the myoepithelial lineage markers.
To learn whether administration of PKF118–310 to tumor-
bearing mice inhibited Wnt/b-catenin signaling in tumors, we
measured the abundance of Wnt/b-catenin target gene transcripts
in the tumor cells. The abundance of both axin2 and cyclin D1
transcripts was significantly lower in tumors harvested from
PKF118–310-treated mice compared to their vehicle-treated
counterparts, confirming that PKF118–310 targeted Wnt/b-
catenin signaling in vivo (Fig. 4F).
The principal objective of our experiments was to learn whether
inhibition of Wnt/b-catenin signaling targeted BTICs in tumors.
Because, treatment with PKF118–310 did not completely shrink
tumors in vivo, we wondered whether PKF118–310 eradicated
functional BTICs in the tumors of treated mice. We reasoned that if
PKF118–310 selectively targeted BTICs in vivo, viable cells isolated
from PKF118–310 treated tumor-bearng hosts would engraft and
elicit tumor growth less efficiently relative to their vehicle-treated
counterparts. To this end, we transplanted tumor cells by injecting
them sub-cutaneously (n=20, PKF118–310-treated; n=20, vehi-
cle-treated) between the shoulders of syngeneic mice (10,000 cells/
mouse) and measured tumor latency in the PKF118–310-treated
and vehicle-treated transplant cohorts. Mice transplanted with
tumor cells harvested from vehicle-treated mice experienced a
Table 1. Wnt/b-catenin pathway genes comprising the gene
signature of differentially expressed genes between
tumorspheres and mammospheres induced to differentiate.
Expressed in tumorspheres
Expressed in mammospheres
induced to differentiate
Wnt7A Sfrp1
Myc Sfrp4
Tle1 Fzd4
Tcf7 Senp2
SLC9A3R1 Pitx2
FZD6 Fshb
Dkk1
Gsk3b
Genes shown are those that were differentially expressed between
tumorspheres and mammospheres induced to differentiate, as assessed by RT-
PCR, and were also present in the NKI dataset.
doi:10.1371/journal.pone.0033976.t001
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tumors after 9 weeks. By contrast, tumor cells harvested from
PKF118–310 treated mice generally failed to initiate tumor growth.
In fact, 85% of mice transplanted with PKF118–310 treated tumor
cells remained tumor free over a 12 week follow-up period (Fig. 5).
The tumors arising following cell transplant were invariably lodged
in the #2 mammary fat pad, which extends from the ventral to the
dorsal area of the host mice (data not shown).
Together with our previous observations, these results demon-
strate that not only was PKF118–310 treatment sufficient to halt
tumor-growth in vivo, but that cells comprising the tumors of mice
administered the compound were substantially diminished in their
capacity to engraft and initiate tumor growth compared to their
vehicle-treated counterparts.
Discussion
Whereas TIC have been identified in a wide variety of human
and mouse malignancies [2,3,4,5,6,8,48,49,50], little is known
Figure 2. Agonists and antagonist of Wnt/b-catenin signaling regulate sphere and colony formation by primary tumor cells and
primary mammary epithelial cells as well as by tumorsphere- and mammosphere-derived cells. A) Wnt3a and Dkk1 inhibit sphere
formation by tumorsphere- and mammosphere-derived cells, compared to bovine serum albumin (BSA) and stem cell media (SCM) controls. B) BIO
stimulates tumorsphere and mammosphere formation. C–D) Sphere formation in the presence of increasing concentrations of PKF118–310, PKF115–
584, and CGP049090. E–F) Colony formation in the presence of increasing concentrations of PKF118–310, PKF115–584, and CGP049090.
doi:10.1371/journal.pone.0033976.g002
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Drug Primary tumor Cells
Primary mammary
epithelial cells Tumorsphere-derived cells Mammosphere-derived cells
PKF118–310 0.58 1.54 0.94 0.54
PKF115–584 0.31 2.05 1.34 1.39
CGP049090 0.84 4.89 1.52 2.64
IC50 calculations for the indicated Wnt/b-catenin pathway inhibitors assessed in sphere forming assays with primary tumor and mammary epithelial cells, as well as
tumorsphere and mammosphere derived cells.
doi:10.1371/journal.pone.0033976.t002
Figure 3. PKF118–310 selectively targets breast TICs in vitro. A) PKF118–310 inhibits sphere formation by primary mammary epithelial cells.
B) PKF118–310 inhibits sphere formation by primary tumor cells. C) PKF118–310 treated primary mammary epithelial cells form spheres with same
efficiency compared to the DMSO vehicle. D) PKF118–310 treated primary tumor cells have little capacity to form spheres compared to the DMSO
vehicle (* p,0.05, t-test). E) Mass (g) of tumors formed from transplant of 1 mM PKF118–310-treated primary tumor cells (* p,0.05, t-test). F) Primary
tumor cells treated with 2.5 mM PKF118–310 are unable to initiate tumor growth after transplant into syngeneic recipient mice.
doi:10.1371/journal.pone.0033976.g003
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identified that selectively target these cells [51,52]. Targeting TICs
is an important cancer therapeutic objective as these cells are
resistant to current cancer therapies, including chemo- and
radiation-therapy [14,17,19,20]. Hence whereas standard thera-
pies result in tumor shrinkage, they may fail to provide long lasting
cures because rare TIC survive and seed tumor relapse.
The use of genomic and drug discovery technologies, such as global
gene expression profiling and high-throughput screening would greatly
aid the search for anti TIC therapies. However, implementation of
these methodologies has been confounded by a lack of suitable human
BTIC-enriched populations for study. Typically BTIC represent an
exceedingly small percentage (,0.01%) of the total tumor cell
population [3,53], and even in the most highly enriched populations,
BTIC rarely achieve more than 1–2% purity [3,53]. Moreover, means
of propagating BTIC-enriched tumor cell populations in vitro have not
been described. To overcome these obstacles, we have studied BTICs
from mouse mammary tumors of breast cancer prone transgenic
models because they comprise a high BTIC frequency, averaging
,30% in most tumors and companion tumorspheres [23].
To determine whether the Wnt/Beta-catenin pathway is
required for the survival and/or self-renewal of BTIC, we
Figure 4. PKF118–310 treatment halts tumor growth. A) Tumor volumes of vehicle and PKF118–310 treated mice. B) Tumor volumes after
completion of treatment (t=12 days) (*p,0.05, t-test). C) PKF118–310 induces formation of duct-like structures (red arrows). D) Photographs of Ki67
stained tumor sections. E) PKF118–310 reduces the fraction of Ki67+ nuclei; quantification of Ki67-positive nuclei was assessed independently by two
different individuals (*p,0.05, t-test). F) Quantification of Wnt target gene expression in tumors isolated from treated and untreated mice using qRT-
PCR (*p,0.05, t-test).
doi:10.1371/journal.pone.0033976.g004
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PKF118–310, PKF115–584 and CGP049090, which were
originally identified in a high throughput screen to identify those
that abrogate the binding of b-catenin to Tcf4 in vitro [45]. Follow
up analyses of these compounds revealed their capacity to: block
b-catenin binding to GST-Tcf4 in vivo; reduce expression of a
Wnt/b-catenin luciferase reporter; restore the b-catenin induced
axis duplication of Xenopus embryos when co-injected with b-
catenin; inhibit expression of the Wnt target genes Myc and
CyclinD1; and retard the proliferation of colon cancer cell lines
known to display hyperactive Wnt signaling in vitro [45].
Collectively, the latter findings suggest that PKF118–310,
PKF115–584 and CGP049090 reduce Wnt/b-catenin signaling
leading to the inhibition of cancer cell line proliferation in vitro.T o
the best of our knowledge the effect of these compounds on breast
tumorigenesis has not previously been assessed.
Several studies have implicated Wnt/b-catenin signaling in both
the pathogenesis of breast cancer and the regulation of normal
mammary epithelial stem cell processes [24,31,54]. Our data
suggests that the Wnt/b-catenin pathway is hyperactive in BTIC
compared to normal mammary epithelial stem/progenitor cells or
to their more differentiated descendants. We made use of the small
molecule inhibitors to investigate the consequences of inhibiting
Wnt/b-catenin signaling in both breast tumor cells and normal
mammary epithelial stem/progenitor cell populations. Due to the
limited availability of the natural compounds PKF115–584 and
CGP049090, we focused primarily on the use of PKF118–310,
which can be chemically synthesized. Our initial experiments
showed that each of the 3 compounds inhibited sphere and colony
formation by primary tumor cells and primary mammary
epithelial cells, as well as by established tumorsphere- and
mammosphere-derived cells without any apparent selectivity.
However, both PKF115–584 and CGP049090 displayed some-
what increased selectivity of between 6–7 fold (IC50
MMS/IC50
TMS,
Table 1) for primary tumor cells over primary mammary epithelial
cells in sphere forming assays compared to PKF118–310 (2–3 fold
selectivity), indicating that further investigation of the potential
selectivity these compounds is warranted.
We did not observe any significant selectivity of PKF118–310
for either the survival and/or self-renewal of tumorsphere-
initiating cells compared to mammosphere-initiating cells in
primary sphere-forming assays (Fig. 2C–F). However, a single
exposure of primary tumor cells to PKF118–310 in a primary
sphere-forming assay was sufficient to block subsequent secondary
sphere formation in the absence of the compound. By contrast,
mammary epithelial cells exposed to PKF118–310 were not
impaired in their capacity to form secondary spheres, suggesting
that the effect of PKF118–310 on secondary sphere formation is
specific to BTICs. Taken at face value these observations suggest
that PKF118–310 inhibited tumorsphere formation by an
irreversible mechanism, whereas the compound acted reversibly
to affect mammosphere formation. Inhibition of Wnt/Beta-
catenin signaling by PKF118–310 may be cytotoxic for tumor-
sphere-initiating cells, perhaps because they are addicted this
pathway, whereas pathway inhibition may be cytostatic for
mammosphere-initiating cells.
Whereas sphere formation is a convenient and relatively rapid
surrogate in vitro assay for stem/progenitor and TIC activity, the
nature of sphere-forming cells is controversial and consequently we
employed additional means to identity the tumor cells that might
be targeted by PKF118–310 [37,38,39,40,55]. To this end we
transplanted primary tumor cell populations that had been
incubated with PKF118–310 under the same conditions as had
been used in primary sphere-forming assays and thereafter
measured the capacity of the remaining viable tumor cells to seed
tumor growth after transplantation into syngeneic FVB/N female
mice. These transplantation assays directly assess BTIC frequency
and demonstrated that PKF118–310 targeted these cells as
manifested by a concentration-dependent reduction in tumor
incidence in recipient mice resulting from transplant of the
compound-treated tumor cells.
Administration of PKF118–310 to tumor-bearing mice blocked
tumor growth during the 10-day treatment period, an interval
during which the tumors expanded by 2–3 fold in tumor-bearing
mice that were administered the vehicle. Histological analyses of
tumor sections from mice administered PKF118–310 revealed loss
of tumor architecture manifested as reduced cellularity and
phenotypic features associated with reduced tumor grade.
Whereas no evidence of apoptotic cell death or altered expression
of differentiation markers was evident in tumor sections from mice
administered the compound (data not shown), the frequency of
Ki67-positive cells, a biomarker of cell proliferation, was markedly
reduced. Importantly, tumor cells harvested from mice exposed to
PKF118–300 formed tumor grafts in only 3 of 20 mice
transplanted with these cells some 2 weeks after tumors had
already formed in 20/20 mice transplanted with vehicle-treated
tumor cells. Our transplantation assay can detect single tumor cells
in the bulk tumor cell population, which on average comprise
,30% functional BTIC as established by limiting dilution cell
transplantation assays [23]. Hence, our findings suggest that the
Figure 5. Tumor cells from PKF118–310 treated tumor-bearing mice engraft and elicit the growth of secondary tumors less
efficiently than their vehicle-treated counterparts. Viable tumor cells were harvested from PKF118–310- and DMSO-treated mice and 10,000
viable tumor cells per mouse were transplanted into syngeneic recipients (n=20 treated/untreated) (* p,0.05, Log-rank test).
doi:10.1371/journal.pone.0033976.g005
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reduced by inhibiting Wnt/Beta-catenin signaling in tumors [23].
Taken together these multiple lines of investigation suggest that
antagonists of Wnt/Beta-catenin signaling target BTIC and
provide proof-of-principle that eradicating these cells leads to
durable breast cancer remission.
Materials and Methods
Care and treatment of animals
All mice used in these experiments were housed in a Canadian
Council on Animal Care (CCAC)-approved facility at McMaster
University. Mice were provided with food and water ad libitum. All
animal experiments were conducted in accordance with the
requirements of the CCAC.
Tumor and mammary epithelial cell culture
The #3 and #4 mammary glands from virgin female FVB/N
mice (6–8 weeks old) and mammary tumors were isolated as
described previously [23,56]. Mammospheres and tumorspheres
were established from the bulk primary mammary epithelial and
tumor cell population respectively as described previously [57].
Serial passage of the mammospheres and tumorspheres was
accomplished by mechanically dissociated the cells from spheres
using titruation and reseeding the dispersed cells into fresh
medium. Passage of the spheres was limited to 3–5 serial passages
before the cells were harvested and RNA prepared. To induce a
differentiation program in mammospheres in vitro, intact mammo-
spheres were collected by centrifugation, the spheres were
dissociated and the dispersed cells were plated at a density of
150,000 cells/ml on rat-tail collagen (Roche, Basel, Switzerland)
coated 60 mm Petri dishes [58,59]. The cells were incubated for a
week before they were harvested and used to prepare cellular
RNA for analyses.
RNA isolation and analyses
Total RNA was isolated from tumorspheres, mammospheres or
mammospheres induced to differentiate using an RNAeasy mini
prep kit (QIAGEN, Hilden, Germany) according to the manu-
facturer’s protocol. RNA was quantified using spectrophotometic
analyses (A260 nm/A280 nm) and it’s quality assessed by gel
electrophoresis. RNA from 3 independent tumorsphere, mammo-
sphere, and mammospheres induced to differentiate cell popula-
tions was used to prepare cRNA probes for hybridization to
MOE430A Gene Chips
TM in accordance with manufacturer’s
protocols (Affymetrix, Santa Clara, California). Gene expression
profiling data was analyzed using Genespring
TM. Gene expression
values were normalized to the average expression of either
mammospheres induced to differentiate or tumorspheres for each
probe set to generate a heat map. When a gene was represented by
multiple probe sets, the most highly differentially expressed probe
set was chosen for display in the heat map. These data have been
deposited in the gene expression omnibus (GEO, GSE32463).
Independent RNA preparations from different populations of
tumorspheres, mammospheres, or mammospheres induced to
differentiate was also analyzed by quantitative RT-PCR using the
mouse Wnt Signaling Pathway RT
2 Profiler
TM (QIAGEN). Total
cellular RNA was isolated using the RNAeasy mini prep kit
(QIAGEN) and used as template for oligo-dT primed reverse
transcription using SuperScriptII
TM First Strand Synthesis (In-
vitrogen, Carlsbad, California) for quantitative RT-PCR The
abundance of selected mRNA transcripts were determined (primer
sequences available upon request) with quantitative RT-PCR
using FastStart DNA Master SYBR Green I Kit on the Light
Cycler (Roche) according to the manufacturer’s protocol.
Gene signature
Microarray and clinical data was downloaded from http://
microarray-pubs.stanford.edu/wound_NKI/explore.html. The
expression of Wnt/b-catenin signaling pathway genes was used
to divide patients into related and unrelated Wnt/b-catenin
signature groups as previously described [36].
Sphere, colony, and ex vivo treatment assays
Sphere and colony forming assays were completed as previously
described [23]. Dkk1 and Wnt3A were obtained from RnDSys-
tems (Minneapolis, Minnesota). PKF118–310, PKF115–584 and
CGP049090 were a gift from Novartis (Basel, Switzerland).
IC50 calculations
The 50% inhibitory concentration (IC50) of compounds was
calculated using GraphPad Prism5 software. X-axis values were
X=Log(X) transformed and then fit with a dose-response curve.
The DMSO vehicle control was included to aid IC50 calculation
and was assigned a 1 nM concentration of the tested compound.
In vivo compound administration
Freshly isolated primary tumor (100,000) cells were suspended
in 50% Matrigel (BD, Franklin Lakes, New Jersey), 45%
phosphate buffered saline pH7.4 (PBS) and 5% fetal bovine
serum (FBS) [Invitrogen, Carlsbad, California], and the cells were
injected subcutaneously between the shoulders into syngeneic 6–8
week-old female mice (FVB/N strain). Mice were monitored by
palpation weekly for the occurrence of tumors. When tumors
reached roughly 1 cm
3, the mice were administered either the
vehicle (0.1% DMSO) or PKF118–310 (0.85 mg/kg) dissolved in
0.1% DMSO by intra-tumoral injection for 5 consecutive days
followed by a 2-day rest period before compound administration
was repeated once. Tumor volume was measured twice weekly. At
the end of the 12-day treatment cycle the mice were sacrificed and
their tumors harvested for analysis. We found that tumors were
invariably embedded in the fat pads of the number 2 mammary
glands. Viable tumor cells (assessed by TrypanBlue staining) from
vehicle- and compound-treated mice were isolated as described
above and 10,000 cells were transplanted subcutaneously into
syngeneic mice (n=20, treated; n=20, untreated).
Histology and immuno-histochemical analysis
Paraformaldehyde fixed tumor fragments were embedded in
paraffin, sectioned and stained with H&E. The tumor sections
were de-paraffinized and rehydrated in ethanol (100-70%
gradient) before immunofluorescent analysis. Antigen retrieval
was performed in Antigen Unmasking Solution (Vector, Burlin-
game, California). Slides were blocked with 3% normal goat serum
(Dako, Denmark) and incubated with primary antibodies for
2 hours at room temperature (Ki67, 1:200 [ABCAM, Cambridge,
Massachusetts]. Secondary antibodies (Invitrogen) were used at a
1:200 dilution for 1 hour at room temperature.
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